These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 37443711)

  • 1. Monocytes in Tumorigenesis and Tumor Immunotherapy.
    Chen X; Li Y; Xia H; Chen YH
    Cells; 2023 Jun; 12(13):. PubMed ID: 37443711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the interactions between platelets with other cells in tumor growth and progression.
    Li Y; Wang H; Zhao Z; Yang Y; Meng Z; Qin L
    Front Immunol; 2023; 14():1165989. PubMed ID: 37153586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monocytes in the Tumor Microenvironment.
    Ugel S; Canè S; De Sanctis F; Bronte V
    Annu Rev Pathol; 2021 Jan; 16():93-122. PubMed ID: 33497262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil Heterogeneity in Cancer: From Biology to Therapies.
    Lecot P; Sarabi M; Pereira Abrantes M; Mussard J; Koenderman L; Caux C; Bendriss-Vermare N; Michallet MC
    Front Immunol; 2019; 10():2155. PubMed ID: 31616408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monocyte heterogeneity and functions in cancer.
    Olingy CE; Dinh HQ; Hedrick CC
    J Leukoc Biol; 2019 Aug; 106(2):309-322. PubMed ID: 30776148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Models for Monocytic Cells in the Tumor Microenvironment.
    Lee SWL; Adriani G; Kamm RD; Gillrie MR
    Adv Exp Med Biol; 2020; 1224():87-115. PubMed ID: 32036607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mild dyslipidemia accelerates tumorigenesis through expansion of Ly6C
    Tran T; Lavillegrand JR; Lereverend C; Esposito B; Cartier L; Montabord M; Tran-Rajau J; Diedisheim M; Gruel N; Ouguerram K; Paolini L; Lenoir O; Pinteaux E; Brabencova E; Tanchot C; Urquia P; Lehmann-Che J; Le Naour R; Merrouche Y; Stockmann C; Mallat Z; Tedgui A; Ait-Oufella H; Tartour E; Potteaux S
    Nat Commun; 2022 Sep; 13(1):5399. PubMed ID: 36104342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Endless Saga of Monocyte Diversity.
    Canè S; Ugel S; Trovato R; Marigo I; De Sanctis F; Sartoris S; Bronte V
    Front Immunol; 2019; 10():1786. PubMed ID: 31447834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Rel-dependent monocytes are potent immune suppressor cells in cancer.
    Li T; Bou-Dargham MJ; Fultang N; Li X; Pear WS; Sun H; Chen YH
    J Leukoc Biol; 2022 Oct; 112(4):845-859. PubMed ID: 35694784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity and origins of myeloid cells.
    Yáñez A; Bono C; Goodridge HS
    Curr Opin Hematol; 2022 Jul; 29(4):201-208. PubMed ID: 35285448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the myeloid microenvironment in neuroblastoma.
    Stip MC; Teeuwen L; Dierselhuis MP; Leusen JHW; Krijgsman D
    J Exp Clin Cancer Res; 2023 Dec; 42(1):337. PubMed ID: 38087370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor signaling to the bone marrow changes the phenotype of monocytes and pulmonary macrophages during urethane-induced primary lung tumorigenesis in A/J mice.
    Redente EF; Orlicky DJ; Bouchard RJ; Malkinson AM
    Am J Pathol; 2007 Feb; 170(2):693-708. PubMed ID: 17255336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy.
    Lu B; Yang M; Wang Q
    J Mol Med (Berl); 2016 May; 94(5):535-43. PubMed ID: 26922618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of monocytes on tumor cell extravasation in a 3D vascularized microfluidic model.
    Boussommier-Calleja A; Atiyas Y; Haase K; Headley M; Lewis C; Kamm RD
    Biomaterials; 2019 Apr; 198():180-193. PubMed ID: 29548546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biophysical heterogeneity of myeloid-derived microenvironment to regulate resistance to cancer immunotherapy.
    Zhao J; Dong Y; Zhang Y; Wang J; Wang Z
    Adv Drug Deliv Rev; 2022 Dec; 191():114585. PubMed ID: 36273512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies.
    Hernandez C; Arasanz H; Chocarro L; Bocanegra A; Zuazo M; Fernandez-Hinojal G; Blanco E; Vera R; Escors D; Kochan G
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32244396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monocyte programming by cancer therapy.
    Patysheva M; Frolova A; Larionova I; Afanas'ev S; Tarasova A; Cherdyntseva N; Kzhyshkowska J
    Front Immunol; 2022; 13():994319. PubMed ID: 36341366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central Roles of STAT3-Mediated Signals in Onset and Development of Cancers: Tumorigenesis and Immunosurveillance.
    Hashimoto S; Hashimoto A; Muromoto R; Kitai Y; Oritani K; Matsuda T
    Cells; 2022 Aug; 11(16):. PubMed ID: 36010693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bi-directional dialog between vascular cells and monocytes/macrophages regulates tumor progression.
    Delprat V; Michiels C
    Cancer Metastasis Rev; 2021 Jun; 40(2):477-500. PubMed ID: 33783686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of Myeloid-derived Suppressor Cells by Long Non-coding RNAs in the Tumor Microenvironment and Tumorigenesis.
    Huo S; Liu L; Li Q; Wang J
    Discov Med; 2022; 33(170):143-151. PubMed ID: 36319601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.